Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

pembrolizumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Docetaxel 3Cisplatin 3Carboplatin 3entrectinib 2Radiotherapy, Intensity-Modulated 2Platinum 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab deruxtecan 1luprolide acetate gel depot 1lenvatinib 1dehydroftorafur 1darolutamide 1ceralasertib 1apalutamide 1amivantamab 1X-Rays 1Surveys and Questionnaires 1Radiotherapy, Conformal 1Radiosurgery 1Pemetrexed 1Leuprolide 1Immunoglobulin G 1Gonadotropin-Releasing Hormone 1Glutamate Carboxypeptidase II 1Fluorouracil 1EBC-46 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Salivary Gland Neoplasms × Glutamate Carboxypeptidase II × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡